Table 2 Lifespan-extending drugs/compounds that might reduce accelerated aging in major depressive disorder, major depressive disorder with comorbid anxiety disorder and cocaine use disorder with high anhedonia.
From: Molecular signatures of premature aging in Major Depression and Substance Use Disorders
Disease | Drug Name | Disease DEGs Drug target | Aging Signature of DEGs in Disease |
|---|---|---|---|
MDD | Ascorbic acid | PLOD1 | upregulated in aging |
Folic acid | FOLR3 | upregulated in aging | |
Zinc acetate | FN1 | upregulated in aging | |
Ascorbic acid | PLOD2 | upregulated in aging | |
Deferoxamine | APP | upregulated in aging | |
Resveratrol | APP | upregulated in aging | |
Zinc acetate | APP | upregulated in aging | |
Chloroquine | HMGB1 | downregulated in aging | |
Genistein | GPER1 | upregulated in aging | |
Estradiol valerate | GPER1 | upregulated in aging | |
MDD with comorbid anxiety disorder | Ascorbic acid | PLOD2 | upregulated in aging |
Deferoxamine | APP | upregulated in aging | |
Resveratrol | APP | upregulated in aging | |
Zinc acetate | APP | upregulated in aging | |
Genistein | GPER1 | upregulated in aging | |
Estradiol valerate | GPER1 | upregulated in aging | |
CUD with high anhedonia | Cysteine | MGMT | downregulated in aging |
Zinc acetate | MGMT | downregulated in aging | |
Vitamin E | DGKA | upregulated in aging | |
Reserpine | BIRC5 | downregulated in aging | |
Berberine | BIRC5 | downregulated in aging |
